A multi-arm(basket)study of IO102-IO103 and Pembrolizumab in 1st line MetastaticNSCLC, SCCHN or UBC
Research type
Research Study
Full title
A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head and Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)
IRAS ID
1003886
Contact name
Andrew Willis
Contact email
Sponsor organisation
IO Biotech ApS
Eudract number
2021-003026-69
Research summary
This is Phase II clinical trial that investigates the safety and efficacy of the combination of new anti-cancer treatment (IO102-IO103) and pembrolizumab. Patients diagnosed with a cancer of the lung (advanced non-small cell lung cancer), a specific type of cancer within the head or neck region (squamous cell carcinoma of the head and neck) or a cancer of the bladder area (metastatic urothelial bladder cancer) will be recruited to this trial.
The trial treatment will be given to participants every 3 weeks for approximately 2 years. However, the length of the patients’ participation will depend on whether they are tolerating the trial drug or if they are responding to the trial treatment.
To be enrolled in the study patients need to meet defined inclusion and exclusion criteria and sign Informed Consent Form. It is estimated that approximately 90 patients will participate in this research trial.
This is a commercial trial fully funded by sponsor, IO Biotech ApS based in Denmark.REC name
London - Westminster Research Ethics Committee
REC reference
21/LO/0544
Date of REC Opinion
7 Sep 2021
REC opinion
Further Information Favourable Opinion